U.S. Markets closed

ABIOMED (ABMD) to Launch Impella CP With SmartAssist at SCAI

Zacks Equity Research

ABIOMED, Inc. ABMD recently announced that its Impella CP with SmartAssist will be commercially available at the 2019 Society for Cardiovascular Angiography & Interventions (“SCAI”) Scientific Sessions. Additionally, majority of the Impella CP heart pumps will be transitioned to SmartAssist in fiscal 2020.

This fortifies ABIOMED’s foothold in the cardiovascular devices market.

Impella CP With SmartAssist

ABIOMED’s Impella CP with SmartAssist is designed to improve patient outcomes using real-time intelligence. Notably, it received FDA approval in 2018 in the United States.

Impella CP with SmartAssist is the only mechanical circulatory support device that calculates and displays left ventricular end-diastolic pressure, mean arterial pressure and cardiac power output. It is known for greater hemodynamic support.

It is encouraging to note that Impella CP received the Japanese PMDA (Pharmaceuticals and Medical Devices Agency) approval in the recently reported fiscal fourth quarter.

Market Prospects

The Business Research Company suggests that the cardiovascular devices market is expected to reach a value of nearly $80.68 billion by 2022, at a CAGR of 5.7%. New health reforms, a growing economy and rising awareness of healthcare fuel growth.

Price Performance

We believe that positive developments such as these will boost the Zacks Rank #4 (Sell) stock, which has lost 31.3% compared with the industry’s 3.1% decline in a year’s time. The current level compares unfavorably with the S&P 500 index’s 4% rally.

Key Picks

A few better-ranked stocks in the broader medical space are DENTSPLY SIRONA XRAY, Masimo Corporation MASI ad CONMED Corporation CNMD, each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

DENTSPLY’s long-term earnings growth rate is expected at 11.5%.

Masimo’s long-term earnings growth rate is projected at 16.1%.

CONMED’s long-term earnings growth rate is estimated at 13.3%.

This Could Be the Fastest Way to Grow Wealth in 2019

Research indicates one sector is poised to deliver a crop of the best-performing stocks you'll find anywhere in the market. Breaking news in this space frequently creates quick double- and triple-digit profit opportunities.

These companies are changing the world – and owning their stocks could transform your portfolio in 2019 and beyond. Recent trades from this sector have generated +98%, +119% and +164% gains in as little as 1 month.

Click here to see these breakthrough stocks now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABIOMED, Inc. (ABMD) : Free Stock Analysis Report
Masimo Corporation (MASI) : Free Stock Analysis Report
DENTSPLY SIRONA Inc. (XRAY) : Free Stock Analysis Report
CONMED Corporation (CNMD) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research